- Email: [email protected]
4717717 Stabilized compositions containing epidermal growth factor
NEW
PATENTS
This Section contains abstracts and, where appropriate, illustrations of recently issued United States patents and published patent applications filed from over 30 countries under the Patent Cooperation Treaty. This information was obtained from recent additions to the Pergamon PATSEARCH” online database in accordance with interest profiles developed by the Editors. Further information about Pergamon PATSEARCH’ can be obtained from Pergamon Orbit InfoLine Inc., 8000 Westpark Drive. McLean, Virginia 22102 U.S.A. Copies of complete patents announced in this Section are available from Pergamon Orbit InfoLine Inc. for $8 per copy. Payment with order is required. Orders outside North America add $2 for air postage. Order by patent number for Pergamon Orbit InfoLine only.
growth factor having an apparent mean molecular weight of about 45 kilodaltons and being funtional to stimulate growth of mast cells.
4717717 STABILIZED COMPOSITIONS CONTAINING EPIDERMAL GROWTH FACTOR Amy
Finkenaur
assigned
to Ethicon
4730036 PURIFICATIONS OF B-CELL INDUCING FACTOR (BIF) AND B-CELL GROWTH FACTOR (BGF)
Inc
Medicinal compositions containing epidermal growth factor are stabilized against loss of biological activity in the presence of moisture by including in said compositions a stabilizing amount of water-soluble cellulose polymer, preferably methylcellulose or a hydroxy alkylcellulose such as hydroxypropyl methylcellulose.
Peter Ralph, Karl Welte assigned to Kettering Institute for Cancer Research
Highly purified T cell replacing factor (TRF or BIF) essentially free Jf IL-2 and Interferon activities is obtained in the invention. BIF is useful for treatment of immunoregulatory disorders and/or stimulation of production of immunoglobulins. A method for production of BIF and BGF is described. B cell lines for BIF assays are described as well as an assay for B cell receptor variants and a method for obtaining B cell variants from a variety of source materials.
4720482 PHARMACEUTICAL COMPOSITIONS CONTAINING ONE OR MORE LYMPHOCYTE GROWTH FACTORS Harvey Farber
I Cantor. Gary Cancer Institute
Nabel
assigned
Sloan-
4742003
to Dana
HUMAN TRANSFORMING GROWTH FACTOR
The present invention is directed to a pharmaceutical composition, comprising a mammalian cell growth factor and a pharmaceutically acceptable carrier. The growth factor of the present Invention is selected from the group comprising; (a) a protein having a molecular weight of about 14 kilodaltons and being functional to stimulate growth of both B and T lymphocytes; (b) a protein having an apparent molecular weight of about 50 kilodaltons and being functional to stimulate growth of B lymphocytes; and (c) a
Rik M Derynck, Genentech Inc Methods and recombinant factor- alpha are useful in bodies raised growth factor-
281
David
Goeddel
assigned
to
compositions are provided for the synthesis of the tumor growth precursor and its fragments. These therapy and diagnosis. as are antiby immunization with the tumor alpha precursor and its fragment,
PATENTS
This Section contains abstracts and, where appropriate, illustrations of recently issued United States patents and published patent applications filed from over 30 countries under the Patent Cooperation Treaty. This information was obtained from recent additions to the Pergamon PATSEARCH” online database in accordance with interest profiles developed by the Editors. Further information about Pergamon PATSEARCH’ can be obtained from Pergamon Orbit InfoLine Inc., 8000 Westpark Drive. McLean, Virginia 22102 U.S.A. Copies of complete patents announced in this Section are available from Pergamon Orbit InfoLine Inc. for $8 per copy. Payment with order is required. Orders outside North America add $2 for air postage. Order by patent number for Pergamon Orbit InfoLine only.
growth factor having an apparent mean molecular weight of about 45 kilodaltons and being funtional to stimulate growth of mast cells.
4717717 STABILIZED COMPOSITIONS CONTAINING EPIDERMAL GROWTH FACTOR Amy
Finkenaur
assigned
to Ethicon
4730036 PURIFICATIONS OF B-CELL INDUCING FACTOR (BIF) AND B-CELL GROWTH FACTOR (BGF)
Inc
Medicinal compositions containing epidermal growth factor are stabilized against loss of biological activity in the presence of moisture by including in said compositions a stabilizing amount of water-soluble cellulose polymer, preferably methylcellulose or a hydroxy alkylcellulose such as hydroxypropyl methylcellulose.
Peter Ralph, Karl Welte assigned to Kettering Institute for Cancer Research
Highly purified T cell replacing factor (TRF or BIF) essentially free Jf IL-2 and Interferon activities is obtained in the invention. BIF is useful for treatment of immunoregulatory disorders and/or stimulation of production of immunoglobulins. A method for production of BIF and BGF is described. B cell lines for BIF assays are described as well as an assay for B cell receptor variants and a method for obtaining B cell variants from a variety of source materials.
4720482 PHARMACEUTICAL COMPOSITIONS CONTAINING ONE OR MORE LYMPHOCYTE GROWTH FACTORS Harvey Farber
I Cantor. Gary Cancer Institute
Nabel
assigned
Sloan-
4742003
to Dana
HUMAN TRANSFORMING GROWTH FACTOR
The present invention is directed to a pharmaceutical composition, comprising a mammalian cell growth factor and a pharmaceutically acceptable carrier. The growth factor of the present Invention is selected from the group comprising; (a) a protein having a molecular weight of about 14 kilodaltons and being functional to stimulate growth of both B and T lymphocytes; (b) a protein having an apparent molecular weight of about 50 kilodaltons and being functional to stimulate growth of B lymphocytes; and (c) a
Rik M Derynck, Genentech Inc Methods and recombinant factor- alpha are useful in bodies raised growth factor-
281
David
Goeddel
assigned
to
compositions are provided for the synthesis of the tumor growth precursor and its fragments. These therapy and diagnosis. as are antiby immunization with the tumor alpha precursor and its fragment,